Early posttransplant rituximab use in kidney transplant recipients with preexisting donor-specific antibodies

The presence of pretransplant anti-human leukocyte antigen (HLA) donor-specific antibodies (DSAs) is still a significant barrier to successful kidney transplantation, as it increases the risk of rejection and graft failure. Rituximab (anti-CD20 antibody) has been administered in hopes of suppressing...

Descrición completa

Detalles Bibliográficos

Principais autores:	Junji Yamauchi, Katalin Fornadi, Divya Raghavan, Duha Jweehan, Suayp Oygen, Silviana Marineci, Ann Pole, Dharmendra Jain, Eszter Lazar-Molnar, Miklos Z. Molnar
Formato:	Artigo
Idioma:	Inglês
Publicado:	Taylor & Francis Group 2026-12-01
Series:	Renal Failure
Assuntos:	Kidney transplantation donor specific antibodies rituximab rejection infection
Acceso en liña:	https://www.tandfonline.com/doi/10.1080/0886022X.2026.2620179
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!